Business Context and Reporting Period
Pulmatrix, Inc., a Delaware corporation, filed this Form 8-K on January 28, 2019, to report the entry into a material definitive agreement. The filing details an underwritten public offering of common stock with H.C. Wainwright & Co., LLC, with an expected closing date of January 31, 2019.
Key Financial Metrics
- Shares Offered: 1,561,177 shares of common stock.
- Public Offering Price: $0.17 per share.
- Underwriter Purchase Price: $0.1581 per share.
- Expected Net Proceeds: Approximately $246,822 (after underwriting discounts and commissions, before offering expenses).
- Underwriter Warrants: Warrants to purchase up to 101,477 shares (7% of the offering size).
- Warrant Exercise Price: $0.2125 per share (125% of the public offering price).
- Warrant Term: Five years from the execution date.
- Additional Costs: Up to $7,700 for legal/out-of-pocket expenses, $10,000 for clearing expenses, and a 1% management fee on gross proceeds.
The filing text does not provide clear values for the company's current revenue, profit, cash flow, margins, or total debt levels.
Material Changes
This filing represents a material change in the company's capital structure through the issuance of new equity. The company is raising capital via a public offering, which will increase the number of outstanding shares and provide immediate liquidity upon closing. No prior comparable period financial data is included in this specific filing to assess year-over-year changes.
Outlook, Risks, and Contingencies
The offering is subject to the satisfaction of customary closing conditions. The Underwriting Agreement includes customary representations, warranties, and indemnification provisions for both the Company and the Underwriter. The issuance of Underwriter Warrants is contingent upon the closing of the offering and is exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
Investor Verification Checklist
- Verify the final closing date of the offering (expected January 31, 2019) and confirm receipt of net proceeds.
- Review the final prospectus supplement for any changes to the offering price or share count.
- Assess the dilution impact of the 1,561,177 new shares and the potential future dilution from the 101,477 underwriter warrants.
- Confirm the company's cash position post-offering to evaluate runway for operations.
- Check for any subsequent filings regarding the use of proceeds or changes in the company's financial condition.